US FDA declines to approve Ultragenyx's gene therapy for rare genetic disorder
Shares of the California-based biopharma company fell 5.4% in extended trading.
The FDA in its "complete response letter" sought additional information related to the company's production processes and facilities. The regulator's decision comes more than a month ahead of the previously announced action date of August 18.
The agency's observations, related to facilities and processes, are addressable and not directly related to the therapy's quality, Ultragenyx said, adding that many of the issues have already been addressed.
"It looks like this is a speed bump to approval, rather than a roadblock," Leerink Partners analyst Joseph Schwartz said in a client note.
The therapy, UX111, was developed to treat a common type of Sanfilippo syndrome — a group of genetic conditions that begin in early childhood causing severe brain damage and early death.
The treatment involves managing symptoms as there are currently no approved disease-modifying medicines.
Ultragenyx said the FDA did not cite any review issues related to the clinical data submitted as part of the marketing application.
The company's application for UX111 was based on trial data that showed the gene therapy significantly reduced toxic buildup in the brain and improved cognitive and communication skills in children with Sanfilippo syndrome type A.
It plans to resubmit updated clinical data from current patients after resolving the FDA's concerns. A new review could take up to six months once the revised application is filed.
Ultragenyx acquired the global rights of the therapy from Abeona Therapeutics (ABEO.O), opens new tab through an exclusive license agreement on 2022.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Reuters
3 hours ago
- Reuters
US FDA's chief medical and science officer Prasad departs agency
July 29 (Reuters) - Vinay Prasad, the U.S. Food and Drug Administration's chief medical and science officer, has left the health regulator, the U.S. Department of Health and Human Services, which oversees the FDA, said on Tuesday, confirming an earlier news report. "Dr. Prasad did not want to be a distraction to the great work of the FDA in the Trump administration and has decided to return to California and spend more time with his family," an HHS spokesperson said in an emailed statement to Reuters. "We thank him for his service and the many important reforms he was able to achieve in his time at FDA.' STAT News first reported about Prasad's departure, saying it came after a number of controversial decisions by the FDA regarding a gene therapy drug for the treatment of Duchenne muscular dystrophy manufactured by Sarepta Therapeutics (SRPT.O), opens new tab. The agency first halted shipments of the drug, called Elevidys, after the deaths of some recipients but rescinded the suspension on Monday. In June, STAT News reported that Prasad was named as the health regulator's chief medical and science officer, citing an internal memo. In May, the FDA named Prasad, an oncologist who previously criticized FDA leadership and COVID-19 mandates, as the director of its Center for Biologics Evaluation and Research.
Daily Mail
5 hours ago
- Daily Mail
The big problem with rising immigration that hurts every Australian
Australia's high immigration has been likened to a Ponzi scheme as a new report reveals record international student numbers are worsening the housing crisis. Digital Finance Analytics boss Martin North says governments rely too much on bringing more people into Australia to make the economy look bigger, even though it means each person is actually worse off. 'When things are looking at bit shaky, what you try and do is pull the levers, the migration lever is an obvious lever at one level because you can do it relatively quickly and the number goes up even if the GDP per capita doesn't go up,' he said. 'To my mind, though, migration is a Ponzi scheme and migration is part of the quantitative growth.' Like a pyramid scheme, a Ponzi scheme benefits those at the top but leaves everyone else worse off. Mr North, a banking expert, said high immigration was like printing money during Covid - it makes things look better at first, but can cause bigger problems like inflation later. MacroBusiness economist Leith van Onselen said bringing in too many migrants was even worse than the financial bubbles created by the money-printing policies used during the pandemic. 'That blows financial bubbles but it doesn't affect your traffic congestion, it doesn't force you to live in a shoe box apartment because you can't afford a house,' he said. 'There's too many people competing with you for a house. It doesn't turn your cities into high-rise, shoebox metropolises.' A new Reserve Bank report has noted international student numbers were still at record highs, and putting pressure on the housing market during a time of high construction costs. In the year to April, 794,113 international students were enrolled in Australia. 'The number of international students onshore is still near record highs, and student visa arrivals have exceeded departures in recent months, suggesting the number of students onshore is growing,' it said. 'In theory, in the face of a relatively fixed supply of housing in the short term, we would expect an increase in international students to put upward pressure on rental demand and rents (all else equal), in the same way that any kind of increase in the renting population would impact demand. 'Capacity constraints, high costs in the construction sector and low levels of building approvals relative to the population may mean the housing supply response could be slower to materialise compared with in the past.' The RBA report, by economists Madeleine McCowage, Harry Stinson and Matthew Fink, also noted international students were more likely to work in the black economy. 'Temporary migrants are much more likely to be paid below-minimum wages, meaning cash-in-hand work may be prevalent,' it said. In the year to May, 447,620 migrants arrived in Australia on a net basis, which was higher than the 335,000 intake for 2024-25 forecast by Treasury in the pre-election March Budget but below the record-high intake of 548,800 in late 2023. With the permanent intake capped at 185,000 for 2024-25, international students make up the majority of permanent and long-term arrivals in Australia. 'International students were an important driver of net overseas migration during this period, accounting for around half of Australia's total net overseas migration,' the RBA report said. AMP chief economist Shane Oliver said high immigration levels were causing Australia's productivity crisis, with the economy suffering a per capita recession from early 2023 until the September quarter of 2024. 'We have partly made up for poor productivity growth by faster population growth, but this does not address living standards per person,' he said. 'Likewise, the slump in productivity has been masked by strong national commodity earnings but we cannot rely on this indefinitely. 'A surging population over the last 20 years with inadequate infrastructure and housing supply has led to urban congestion and poor housing affordability which contribute to poor productivity growth – notably via increased transport costs and speculative activity around housing diverting resources from more productive uses.' Mr van Onselen said international students were coming to Australia hoping for a pathway to permanent residency or citizenship, with universities benefiting from having overseas students willing to pay fees upfront. 'The whole idea is to encourage a bunch of students, primarily from south Asia, who tend to come to places like Australia and New Zealand, Canada etc for work rights and permanent residency instead of studying,' he said. 'That's their primary goal. They want to attract those people. 'So, they want to expand work rights for international students from 20 hours a week to 25 and effectively turn student visas into de facto low-skilled work visas and residency visas.' International students on a visa can work 48 hours a fortnight if they are studying a Masters degree, with no more than 30 hours of work allowed in the second and third weeks of a month.
Daily Mail
10 hours ago
- Daily Mail
Inside the wildly popular gas station drug RFK Jr. wants to ban to prevent the next opioid crisis
Robert F. Kennedy Jr. is cracking down on an opioid-like substance that has gone wildly viral for its addictive properties, misleading marketing and its wide availability. The Department of Health and Human Services recommended on Tuesday that the Drug Enforcement Agency schedule 7-hydroxymitragynine (7-OH) - a compound that appears in kratom leafs - as a class one illicit substance. Kennedy says the hope is that scheduling it as a controlled substance will help 'prevent the fourth wave of addiction' in the U.S. and Food and Drug Commissioner Marty Makary says it's 13 times more potent than morphine. Currently, drinks, gummies and supplements with trace amounts of 7-OH from the kratom plant are widely available for purchase at smoke shops and convenience stores. Some kratom plant products – like Feel Free botanical tonics – have recently gone viral with consumers claiming they quickly became addicted and dependent on the substance available at their local gas stations. HHS recognizes the increase in reports of overdoses and emergency room visits linked to products containing 7-OH, many times from young people, veterans and people suffering from chronic pain. Many who consume 7-OH claim they were not aware they were taking an addictive product. Others who bought it thought they were purchasing a product with the potency of an energy drink. RFK Jr. and Makary warn that if 7-OH is allowed to remain on shelves, it will result in another opioid-crisis like in the 1990s and 2010s. During a Tuesday press conference, the two officials announced they are initiating the process to have the DEA classify 7-OH as an illegal controlled substance. They cited its opioid-like effects on the brain as justification for the scheduling. It can take months and even years for drugs to get official scheduling by the DEA, but leadership at HHS and FDA make clear that this is a priority and suggest the process will be expedited. The DEA must review the recommendation, which can take between two and six months. Then the rule must be opened for a public comment period, which is between 30 and 60 days. During this time, advocates for the use of kratom leaf are likely to come out in opposition of the drug classification. There are many kratom leaf products, like teas and other drinks, that do not fall in the same category as products that have trace amounts of 7-OH. Makary made very clear that the FDA was not focusing on kratom leaf and only the 7-OH compound. Companies that use kratom leaf with trace amounts of 7-OH in their products claim they help with relaxation and pain, as well as assist with productivity and focus. Makary said: '7-OH is not just like an opioid, it does not just have opioid binding properties. 7-OH binds to the mu receptor, which means, scientifically by definition, it is an opioid.' Products with 7-OH claim to help people with relaxation, pain management, productivity and focus. FDA Commissioner Marty Makary said at a press conference on Tuesday: '7-OH binds to the mu receptor, which means, scientifically by definition, it is an opioid' 'And yet it is sold in vape stores, in smoke shops and convenience stores and gas stations that are popping up all over the United States, and nobody knows what it is,' Markay lamented during a press conference at the HHS building on Tuesday. 'It is a synthetic concentrated by-product of kratom. Our focus is not on kratom. Our focus is on 7-OH,' he added. Deputy HHS Secretary Jim O'Neill warned: '7-OH carries a high risk of addiction, on purpose. It is a powerful opioid agonist, many times more potent than morphine,' sold online and in stores with no quality or dosage constraints. 'Young people, veterans and people who suffer from chronic pain or addiction are being misled into thinking that these are safe alternatives. They are not,' he concluded. RFK Jr. opened up about his years-long struggle with heroin addiction and said part of the HHS effort to schedule 7-OH is also to educate the American public about the threat it poses. 'When there is availability that can become a crisis,' Secretary Kennedy said. 'And my addiction started because of, let me say this, it was precipitated by availability.' Kennedy said that he met with Attorney General Pam Bondi this week regarding the action and that she showed the correlation between a high concentration of vape and smoke shops to areas where addiction-related deaths are happening in higher volumes. 'Vape stores are popping up in every neighborhood in America, and many are selling addictive products like concentrated 7-OH,' Makary said. 'After the last wave of the opioid epidemic, we cannot get caught flat-footed again.'
